How have IGC shares performed in 2024?

IGC Pharma's stock was trading at $0.3446 on January 1st, 2024. Since then, IGC shares have increased by 38.7% and is now trading at $0.4778. View the best growth stocks for 2024 here .

Are investors shorting IGC Pharma?

IGC Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 938,800 shares, an increase of 10.6% from the March 15th total of 848,500 shares. Based on an average daily trading volume, of 740,100 shares, the short-interest ratio is presently 1.3 days. View IGC Pharma's Short Interest .

How were IGC Pharma's earnings last quarter?

IGC Pharma, Inc. (NYSEAMERICAN:IGC) issued its quarterly earnings data on Wednesday, February, 14th. The construction company reported ($0.09) earnings per share (EPS) for the quarter. The construction company had revenue of $0.20 million for the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 110.37% and a negative net margin of 1,163.24%.

What other stocks do shareholders of IGC Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH) , Alibaba Group (BABA) , Tilray (TLRY) , Cronos Group (CRON) , Micron Technology (MU) , NewAge (NBEV) , Advanced Micro Devices (AMD) , Ford Motor (F) and NIO (NIO) .

How do I buy shares of IGC Pharma?

Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:IGC

IGC Pharma (IGC) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free IGC Stock Alerts

$0.48

+0.00 (+0.13%)

(As of 02:32 PM ET)

Compare

Today's Range: $0.47
▼
$0.49
50-Day Range: N/A
52-Week Range: $0.25
▼
$0.91

Volume: 367,549 shs
Average Volume: 809,953 shs
Market Capitalization: $30.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines Ownership SEC Filings Short Interest

Get IGC Pharma alerts:

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About IGC Pharma Stock (NYSEAMERICAN:IGC)

IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IGC Stock News Headlines

April 18, 2024 | americanbankingnews.com

IGC Pharma (NYSEAMERICAN:IGC) Coverage Initiated by Analysts at StockNews.com

April 17, 2024 | msn.com

CDC investigating reports of counterfeit or mishandled Botox injections in 9 states

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 17, 2024 | americanbankingnews.com

Short Interest in IGC Pharma, Inc. (NYSEAMERICAN:IGC) Expands By 10.6%

April 16, 2024 | benzinga.com

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation

April 16, 2024 | stockhouse.com

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

April 16, 2024 | finance.yahoo.com

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

April 14, 2024 | americanbankingnews.com

IGC Pharma (NYSEAMERICAN:IGC) Coverage Initiated at StockNews.com

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 9, 2024 | barrons.com

IGC Pharma Inc.

April 9, 2024 | businesswire.com

IGC Pharma Adds Advisor in Artificial Intelligence

April 2, 2024 | benzinga.com

IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research

March 28, 2024 | msn.com

All About Kyle Richards' Mom Kathleen Richards

March 26, 2024 | businesswire.com

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

March 20, 2024 | msn.com

Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo

March 20, 2024 | msn.com

EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success

March 20, 2024 | finance.yahoo.com

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

March 20, 2024 | businesswire.com

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

March 20, 2024 | businesswire.com

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

March 12, 2024 | finance.yahoo.com

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline

March 12, 2024 | businesswire.com

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

February 28, 2024 | marketwatch.com

IGC Pharma Sees Positive Memory Function Data in Preclinical Study of Alzheimer's Disease Drug

February 28, 2024 | finance.yahoo.com

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

February 23, 2024 | finance.yahoo.com

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price Target

February 23, 2024 | businesswire.com

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

February 19, 2024 | benzinga.com

IGC Pharma Stock (AMEX:IGC) Dividends: History, Yield and Dates

February 19, 2024 | benzinga.com

IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses

See More Headlines

Receive IGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/19/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:IGC
CUSIP: N/A
CIK: 1326205
Web: www.igcinc.us
Phone: (301) 983-0998
Fax: 240-465-0273
Employees: 61
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,510,000.00
Net Margins: -1,163.24%
Pretax Margin: -1,163.24%
Return on Equity: -110.37%
Return on Assets: -93.34%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 1.85
Quick Ratio: 0.86

Sales & Book Value

Annual Sales: $910,000.00
Price / Sales: 33.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.28 per share
Price / Book: 1.70

Miscellaneous

Outstanding Shares: 63,730,000
Free Float: 51,625,000
Market Cap: $30.34 million
Optionable: Not Optionable
Beta: 1.71

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Ram Mukunda (Age 65)
President, CEO & Director
Comp: $705k
Ms. Claudia Grimaldi (Age 53)
VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director
Comp: $245k
Mr. Rohit Goel (Age 30)
Senior Director of Accounting & Principal Accounting Officer

Key Competitors

View All Competitors

IGC Stock Analysis - Frequently Asked Questions

How have IGC shares performed in 2024?: IGC Pharma's stock was trading at $0.3446 on January 1st, 2024. Since then, IGC shares have increased by 38.7% and is now trading at $0.4778.
View the best growth stocks for 2024 here.
Are investors shorting IGC Pharma?: IGC Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 938,800 shares, an increase of 10.6% from the March 15th total of 848,500 shares. Based on an average daily trading volume, of 740,100 shares, the short-interest ratio is presently 1.3 days.
View IGC Pharma's Short Interest.
How were IGC Pharma's earnings last quarter?: IGC Pharma, Inc. (NYSEAMERICAN:IGC) issued its quarterly earnings data on Wednesday, February, 14th. The construction company reported ($0.09) earnings per share (EPS) for the quarter. The construction company had revenue of $0.20 million for the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 110.37% and a negative net margin of 1,163.24%.

What other stocks do shareholders of IGC Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO).
How do I buy shares of IGC Pharma?: Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:IGC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IGC Pharma (IGC) Stock Price, News & Analysis

About IGC Pharma Stock (NYSEAMERICAN:IGC)

IGC Stock Price History

IGC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

IGC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info